Join the India Equity Telegram Group for analysis, updates and results
JAGSNPHARM has declared results for the period ended Sep 2021.
Quarterly Results
[s2If !current_user_can(access_s2member_level1)] Register and Login below to read result analysis [lwa][/s2If] [s2If current_user_can(access_s2member_level1)]
- Sales for period ended Sep 2021 is Rs 59.49 cr compared to Rs 56.35 cr for period ended Sep 2020, a rise of 5.6%
- Operating Profits reported at Rs 10.28 cr for period ended Sep 2021 vis-vis 4.84 for period ended Sep 2020 .
- Operating Margins expanded 869.1 bps for period ended Sep 2021 vis-vis Sep 2020 .
- The EPS for Sep 2021 was Rs 2.79 compared to Rs 2.61 for previous quarter ended Jun 2021 and Rs 1.53 for Sep 2020
- The stock is trading at Rs 162.15 and a market cap of Rs 424 cr
[/s2If]
Trading Chart
Further analysis and Full Company Research with investing scores is available here: JAGSNPHARM
Join BharatEquity Telegram Channel for updated India results, analysis and News
Join Our Twitter
